Lisa LaVange, a director at Simulations Plus , Inc. (NASDAQ:SLP), recently sold 650 shares of the company's common stock. The company, currently valued at $628.5 million, maintains a strong financial position according to InvestingPro data, with a "GOOD" overall health score and healthy liquidity metrics. The shares were sold at a price of $31.88 each, amounting to a total transaction value of $20,722. Following this sale, LaVange retains ownership of 7,150 shares. The stock currently trades at a relatively high P/E ratio of 62.5, suggesting premium valuation levels. InvestingPro analysis reveals 12 additional key insights about SLP's valuation and growth prospects. The transaction was executed under a prearranged trading plan, known as a Rule 10b5-1 plan, which allows insiders to set up a predetermined schedule for selling stocks. For comprehensive analysis of SLP's insider trading patterns and financial metrics, access the full Pro Research Report available on InvestingPro.
In other recent news, Simulations Plus has secured a grant from the U.S. Food and Drug Administration for a collaborative project with the University of Strathclyde and InnoGI Technologies. The project aims to enhance the understanding and prediction of amorphous solid dispersion (ASD) drug formulations under various conditions.
Simulations Plus reported an 18% rise in total revenue to $70 million for fiscal year 2024, with a fourth-quarter revenue increase of 19% to $18.7 million. However, these results fell short of the $19.7 million expected by BTIG and the consensus estimate. Despite this, the company issued financial guidance for fiscal year 2025 that included revenue projections aligning with initial estimates and an adjusted earnings per share (EPS) forecast between $1.07 and $1.20.
The company's strategic acquisitions of Pro-ficiency and Immunetrics have expanded its market and enhanced its software offerings. Simulations Plus projects a revenue of $90 million to $93 million for fiscal year 2025, indicating a growth of 28% to 33% year-over-year.
BTIG has adjusted the financial outlook for Simulations Plus, reducing the price target to $50.00 from the previous $60.00, while maintaining a Buy rating on the stock. These recent developments reflect the company's ongoing financial performance and market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.